Showing 1 – 20 of 321
Best Match | Most Recent | Oldest |
  • Accuracy of Reports of Lifetime Mental and Physical Disorders: Results From the Baltimore Epidemiological Catchment Area Study

    Abstract Full Text
    free access
    JAMA Psychiatry. 2014; 71(3):273-280. doi: 10.1001/jamapsychiatry.2013.3579

    Takayanagi et al examine the lifetime prevalence estimates of mental and physical disorders during midlife to late life using both retrospective and cumulative evaluations. Compton and Lopez provide commentary in a related editorial.

  • Cancer-Related Mortality in People With Mental Illness

    Abstract Full Text
    free access
    JAMA Psychiatry. 2013; 70(2):209-217. doi: 10.1001/jamapsychiatry.2013.278
    Kisely et al assess why psychiatric patients are no more likely than the general population to develop cancer but are more likely to die of it.
  • Suicide Risk in Primary Care Patients With Major Physical Diseases: A Case-Control Study

    Abstract Full Text
    free access
    Arch Gen Psychiatry. 2012; 69(3):256-264. doi: 10.1001/archgenpsychiatry.2011.1561
  • Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

    Abstract Full Text
    free access
    Arch Gen Psychiatry. 2011; 68(1):71-78. doi: 10.1001/archgenpsychiatry.2010.116

    Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer.


    To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety.


    A double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) of psilocybin.


    A clinical research unit within a large public sector academic medical center.


    Twelve adults with advanced-stage cancer and anxiety.

    Main Outcome Measures

    In addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment.


    Safe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance.


    This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field.

    Trial Registration Identifier: NCT00302744

  • Risk of Malignancy in Patients With Schizophrenia or Bipolar Disorder: Nested Case-Control Study

    Abstract Full Text
    free access
    Arch Gen Psychiatry. 2007; 64(12):1368-1376. doi: 10.1001/archpsyc.64.12.1368
  • Relative Risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database

    Abstract Full Text
    free access
    Arch Gen Psychiatry. 2007; 64(2):242-249. doi: 10.1001/archpsyc.64.2.242
  • Dopamine Antagonists and the Development of Breast Cancer

    Abstract Full Text
    free access
    Arch Gen Psychiatry. 2002; 59(12):1147-1154. doi: 10.1001/archpsyc.59.12.1147
  • Incidence of Cancer Among Persons With Schizophrenia and Their Relatives

    Abstract Full Text
    free access
    Arch Gen Psychiatry. 2001; 58(6):573-578. doi: 10.1001/archpsyc.58.6.573
  • Schizophrenia and Cancer: Is There a Need to Invoke a Protective Gene?

    Abstract Full Text
    Arch Gen Psychiatry. 2001; 58(6):579-580. doi: 10.1001/archpsyc.58.6.579
  • JAMA Psychiatry

    Figure: Cancer-Related Mortality in People With Mental Illness

    Figure 1. Survival since diagnosis of all cancers by contact with mental health services. WA indicates Western Australia.
  • JAMA Psychiatry

    Figure: Risk of Malignancy in Patients With Schizophrenia or Bipolar Disorder: Nested Case-Control Study

    Adjusted odds ratios (ORs) for each cancer for patients with schizophrenia (S) and bipolar disorder (B) compared with patients without mental health problems. Error bars represent 95% confidence intervals.
  • JAMA Psychiatry

    Figure: Using Chronic Pain to Predict Depressive Morbidity in the General Population

    Associations between medical conditions and chronic painful physical conditions in 3140 subjects with at least 1 depressive symptom (A) and 748 subjects with major depressive disorder (B), including 76 subjects with a mood disorder due to a general medical condition (major depressivelike episode: endocrine condition, 9 subjects; heart disease, 53 subjects; cancer, 3 subjects; and another disease, 11 subjects).
  • JAMA Psychiatry

    Figure: Cumulative vs Retrospective Lifetime Prevalence of Mental and Physical Disorders at Each Wave

    Cumulative vs retrospective lifetime prevalence at each wave is shown for mental disorders, including major depressive disorder (A), obsessive-compulsive disorder (OCD) (B), panic disorder (C), social phobia (D), alcohol abuse or dependence (E), and drug abuse or dependence (F), and for physical disorders, including diabetes mellitus (G), hypertension (H), arthritis (I), stroke (J), and cancer (K). Wave 1 took place in 1981; wave 2, 1982; wave 3, 1993 to 1996; and wave 4, 2004 to 2005.
  • JAMA Psychiatry

    Figure: Cumulative Hazard Plots by Abuse Group

    A, Plot of cumulative mortality hazard by years since study entry for women with and without reported severe childhood physical abuse. B, Cumulative mortality hazard for women with all types of reported childhood abuse (emotional, moderate physical, and severe physical), some types of reported abuse, and no reported abuse. Analyses control for age, race/ethnicity, education, history of heart disease, history of cancer, alcohol use, and smoking.
  • JAMA Psychiatry

    Figure: Increased Mortality Risk in Women With Depression and Diabetes Mellitus

    Multivariate relative risks and 95% confidence intervals (error bars) of cardiovascular disease (CVD) mortality. A, Relative risk of CVD mortality according to diabetes duration stratified by depression. B, Relative risk of CVD mortality according to diabetes treatment stratified by depression. C, Relative risk of CVD mortality according to depression categories stratified by diabetes. Relative risks were adjusted for age (continuous), family history of diabetes and cancer, parental history of myocardial infarction, current marital status, ethnicity (white or other), body mass index (calculated as weight in kilograms divided by height in meters squared) categories (<23, 23.0-24.9, 25.0-29.9, 30.0-34.9, or ≥35; physical activity level (<3, 3-8.9, 9-17.9, 18-26.9, or ≥27 metabolic equivalent hours per week), alcohol consumption (none, 0.1-4.9 g/d, or ≥5.0 g/d), smoking status (never, past, or current), current multivitamin use (yes or no), current estrogen hormone use (never, past, or current), current aspirin use (yes or no), and major comorbidities, including hypertension, hypercholesterolemia, heart disease, stroke, and cancer.
  • Association of Hormonal Contraception With Depression

    Abstract Full Text
    online first
    JAMA Psychiatry. 2016; doi: 10.1001/jamapsychiatry.2016.2387

    This nationwide cohort study investigates whether the use of hormonal contraception is positively associated with subsequent use of antidepressants and a diagnosis of depression among women in Denmark.

  • Association Between Religious Service Attendance and Lower Suicide Rates Among US Women

    Abstract Full Text
    JAMA Psychiatry. 2016; 73(8):845-851. doi: 10.1001/jamapsychiatry.2016.1243

    This longitudinal prospective study uses data from the Nurses’ Health Study to examine the association between religious service attendance and suicide and the joint associations of suicide with service attendance and religious affiliation.

  • Premature Mortality Among Adults With Schizophrenia in the United States

    Abstract Full Text
    JAMA Psychiatry. 2015; 72(12):1172-1181. doi: 10.1001/jamapsychiatry.2015.1737

    This population epidemiology study of patients with schizophrenia uses Medicaid data to compare overall and cause-specific mortality rates for adults with schizophrenia vs the US general population between 2001 and 2007.

  • Are There Still Too Few Suicides to Generate Public Outrage?

    Abstract Full Text
    JAMA Psychiatry. 2016; 73(10):1003-1004. doi: 10.1001/jamapsychiatry.2016.1736

    This Viewpoint addresses suicide prevention in the context of successful lay-led disease advocacy efforts.

  • Self-injury Mortality in the United States in the Early 21st Century: A Comparison With Proximally Ranked Diseases

    Abstract Full Text
    JAMA Psychiatry. 2016; 73(10):1072-1081. doi: 10.1001/jamapsychiatry.2016.1870

    This population epidemiology study uses data from the US Centers for Disease Control and Prevention to compare trends and patterns of mortality from self-injury with those from diabetes, influenza and pneumonia, and kidney disease between 1999 and 2014.